PRIMA is one of @TIME's Best Inventions of 2026. As the first brain-computer interface approved for commercial use in Europe for the restoration of central vision, PRIMA has given clinical trial patients with geographic atrophy the ability to read letters, numbers, and words again.

German Design Awards 2027 named our Axon Terminal as Winner in Excellent Product Design – Medical, Rehabilitation and Health Care.

Last week at @EURETINA 2026 in Vienna, researchers and clinicians behind the PRIMA clinical program shared the latest research and clinical developments across nine scientific sessions. Thank you to everyone who joined us in Vienna.

Today at @EURETINA 2026, the latest PRIMA clinical trial data will be presented during the Industry Symposium “PRIMA Retinal Implant in Geographic Atrophy: Pivotal Trial Evidence and 36-Month Outcomes.”

Mahi Muqit, MD, PhD, will present the 36-Month outcomes from the PRIMA clinical trial today at @EURETINA 2026 in Vienna. See the full list of PRIMA sessions in the link in the comments.

At @EURETINA 2026 in Vienna this week, researchers and clinicians behind the PRIMA clinical program will present across nine sessions. See the full PRIMA program in the comments.

This week at DOG Deutsche Ophthalmologische Gesellschaft 2026 in Berlin, researchers and clinicians behind the PRIMA clinical program shared the latest research and clinical developments across nine scientific sessions. Thank you to DOG and the physicians, researchers and broader ophthalmology community who joined us this week. Learn more about PRIMA in the link in the comments.

Frank G. Holz, MD, Armin Wolf, MD, and Boris Stanzel, MD, PhD, will present “PRIMA Retinal Implant in Geographic Atrophy: From Pivotal Trial Data to the Clinic” today at DOG Deutsche Ophthalmologische Gesellschaft 2026 in Berlin. The session will conclude with an expert panel on the future of the GA treatment algorithm and retinal specialist referral pathways. See the full list of PRIMA sessions at DOG 2026 in the link in the comments.